title: Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1.
abstract: An application claims non-naturally occurring upregulators of apolipoprotein A-I (ApoA-l) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-l, and can potentially treat and prevent cardiovascular disease and related disease states, including cholesterol or lipid-related disorders, such as atherosclerosis. This application of Resverlogix Corp. increases the diversity of quinazolin-4(3H)-ones capable of upregulating the expression of endogeneous ApoA-l.
authors.affiliation: Capital Medical University, College of Pharmaceutical Sciences, Beijing 100069, PR China.
authors.forename: Jianhui
authors.initials: J
authors.lastname: Wu
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.forename: Shiqi
authors.initials: S
authors.lastname: Peng
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000235:genetics*; D003324:Coronary Artery Disease / Q000188:drug therapy; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D010330:Patents as Topic; D052999:Quinazolinones / Q000737:chemistry / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D016632:Apolipoprotein A-I; D052999:Quinazolinones